Halozyme Reports Record 2025 Revenue, Reiterates Strong 2026 Guidance with Significant Growth

summarizeSummary

Halozyme Therapeutics reported record full-year 2025 revenue of $1.4 billion, driven by its ENHANZE business, and reiterated its robust 2026 financial guidance projecting substantial growth in revenue, EBITDA, and non-GAAP EPS.

check_boxKey Events

• Record 2025 Revenue Achieved

  Halozyme reported record full-year 2025 total revenue of $1.4 billion, a 38% increase year-over-year, primarily driven by continued growth in its ENHANZE business and partner product sales.

• Strong 2026 Guidance Reiterated

  The company reiterated its robust 2026 financial guidance, projecting total revenue of $1.71 billion to $1.81 billion (22-30% YOY growth) and non-GAAP diluted EPS of $7.75 to $8.25 (87-99% YOY growth). This follows the significant guidance raise on January 28, 2026.

• Acquisition Impact on 2025 Earnings

  Full-year 2025 GAAP diluted EPS of $2.56 and Non-GAAP diluted EPS of $4.15 were negatively impacted by a significant $284.9 million acquired in-process research and development (IPR&D) expense related to the Surf Bio acquisition, leading to a net loss in Q4 2025.

• Strategic Portfolio Expansion

  Halozyme completed the acquisitions of Elektrofi's Hypercon™ Technology and Surf Bio's hyperconcentration technology in late 2025, expanding its drug delivery technology portfolio to extend long-term royalty opportunities into the mid-2040s.

auto_awesomeAnalysis

Halozyme Therapeutics delivered strong full-year 2025 financial results, achieving record total revenue of $1.4 billion, a 38% increase year-over-year, primarily fueled by its ENHANZE business and partner product sales. While GAAP and Non-GAAP diluted EPS for 2025 saw a decline due to a significant $284.9 million acquired in-process research and development (IPR&D) expense related to the Surf Bio acquisition, the underlying business performance remains robust. Crucially, the company reiterated its previously strong 2026 financial guidance, projecting total revenue growth of 22% to 30% and non-GAAP diluted EPS growth of 87% to 99%. This reiteration, following the initial guidance raise on January 28, 2026, reinforces investor confidence in the company's future growth trajectory and the long-term value of its expanded drug delivery technology portfolio. The substantial investment in acquisitions like Elektrofi and Surf Bio, while impacting short-term profitability, is aimed at diversifying and extending long-term royalty opportunities.